Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. Among authors: haffner sm. J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22333485 Free article. Clinical Trial.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. Among authors: haffner sm. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121378 Free article. Clinical Trial.
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.
Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N. Seferovic JP, et al. Among authors: haffner sm. Diabetologia. 2018 Mar;61(3):581-588. doi: 10.1007/s00125-017-4485-y. Epub 2017 Nov 3. Diabetologia. 2018. PMID: 29098323 Clinical Trial.
Dual renin-angiotensin system blockade and kidney disease.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA. Parving HH, et al. Among authors: haffner sm. J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. doi: 10.1016/j.jacc.2009.02.074. J Am Coll Cardiol. 2009. PMID: 19589445 Free article. No abstract available.
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
Malachias MVB, Jhund PS, Claggett BL, Wijkman MO, Bentley-Lewis R, Chaturvedi N, Desai AS, Haffner SM, Parving HH, Prescott MF, Solomon SD, De Zeeuw D, McMurray JJV, Pfeffer MA. Malachias MVB, et al. Among authors: haffner sm. J Am Heart Assoc. 2020 Oct 20;9(19):e017462. doi: 10.1161/JAHA.120.017462. Epub 2020 Sep 23. J Am Heart Assoc. 2020. PMID: 32964800 Free PMC article. Clinical Trial.
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM, Boolell M, Haffner SM, Bethel M, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Califf RM, et al. Among authors: haffner sm. Am Heart J. 2008 Oct;156(4):623-32. doi: 10.1016/j.ahj.2008.05.017. Am Heart J. 2008. PMID: 18946890 Clinical Trial.
619 results